Acquisition of CaridianBCT Holding Corp.

Transcription

1 Press Conference & Analyst Meeting Acquisition of CaridianBCT Holding Corp. Terumo Corporation March 7, 2011

2 Summary of Acquisition Target Company: CaridianBCT Holding Corp. (US) Seller Company: Purchase Price: Gambro AB (Sweden) US$2,625M in Cash Anticipated Closing: April-May,

3 Pursue Terumo s Growth Strategy 3

4 M&A Strategy for New growth opportunities 5 Fields of Focus Transfusion as a key element of healthcare infrastructure Global Leader * May, 2010 IR Presentation Accelerate Growth strategy for 5 Fields of focus through Organic growth, Alliance and M&A 4

5 Another Growth Engine New Growth Engine May, 2010 IR Presentation 5

6 Purposes of Acquisition Contribute to the expansion of healthcare worldwide Developed Countries: Aging populations Emerging Countries: Healthcare infrastructure development Participate in specialized market growth Significant synergy potential both in technologies and sales Products: Existing products and new technology Regions: From emerging countries to developed countries 6

7 Corporate Growth Strategies Cardiac & Vascular Blood Transfusion General Hospital Diabetes Care Emerging Market Accelerate Innovations To be a Global Leader Global Drug & Devices Elderly Care, Post-acute Care Expanding Global Demand China, India and Brazil 7

8 Blood Management Business

9 Blood Transfusion Market Blood Collection Centrifugation Storage Transfusion Blood Transfusion is essential to Healthcare Global demand for Blood Transfusion is expanding Specialized market 9

10 Terumo Transfusion Products Auto. Processing System Auto Blood Collection Blood Bag System Sterile Connection Welder

11 CaridianBCT Products Auto Blood Collection Therapeutic Apheresis Pathogen Reduction Whole Blood Processing Cell Expansion System Launched in 2010

12 Overview of CaridianBCT 12

13 Headquarters: Lakewood, Colorado, US (Private) Finance: Sales: US$524M (FY2010) CAGR12% (Ten years) Operating Income: US$126M (FY2010) Facilities: Employees: CEO: Branches in 32 Countries Plants (US, UK) approx people David Perez Pre-Audit Data 13

14 Customer Segments Established markets Newly Entered Markets Blood Bank Automated Collection 64% 24% Hospital / Biolab Therapeutic Apheresis PRT Whole Blood Processes Cell Expansion System 7% Recently Launched Figures are Composition ratio 14

15 Access to CaridianBCT s innovative R&D capabilities and novel high potential technologies An innovative total solution company which provides Automated collection system, Disposable kit and software. Focused on Platelet Market 64% of sales come from Automated Collections business. This core business focuses on high value products which allow blood banks to automatically collect any blood component, in any combination. As a result, CaridianBCT continues to add to its market leading position. 15

16 Effects of Acquisition Terumo + CaridianBCT Blood Management Business 16

17 Create the Leading Global Provider to the Blood Transfusion Industry (US$M) CaridianBCT Terumo (US$M) Europe US Japan ROW Number One Player Sales: US$820M Enhance Global Presence Competitive Products in Platelet Segment CaridianBCT Terumo Regional Synergy Among Emerging countries to Developed countries Total

18 Strong Growth in Blood Transfusion Market Aging Developed Counties Increase in Cancer Therapies (Chemo/Radio) Increase in Platelet Demand Core business of CaridianBCT Population Expansion and rising Medical Standard improvement in Emerging Countries From Basics to High value-added Products Terumo + CaridianBCT = Full Range Products Terumo Manual Emerging Semi-Automated CaridianBCT Automated Developed 18

19 Development in New Technologies Whole Blood Processing Pathogen Reduction Cell Expansion

20 One Big Step Forward for Globalization Consolidation of both transfusion business into one. Obtain strong business management team and global business infrastructures. 20

21 Effects of Acquisition Create the leading global provider to the blood transfusion industry Double Digit Growth in Growing Market Evolve Terumo s Global Management 21

22 Financial Impact Impact on Earnings Details of the impact from goodwill and intangible asset will be announced once determined Impact on EPS Accretive to EPS before amortization of goodwill by the end of fiscal year ending March, 2012 Shareholder Return Stable dividend level in the near term 22

23 Disclaimer regarding forward-looking statements This announcement contains certain forward-looking statements. These forward-looking statements may be identified by words such as expects, expected, will, would, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, including but not limited to: (1) macroeconomic condition and general industry conditions such as the competitive environment for medical equipment business; (2) regulatory and litigation matters and risks; (3) legislative developments; (4) changes in tax and other laws and the effect of changes in general economic conditions; (5) the risk that a condition to closing of the Acquisition may not be satisfied; (6) the risk that a regulatory approval that may be required for the Acquisition is not obtained or is obtained subject to conditions that are not anticipated; and (7) other risks to consummation of the Acquisition. Terumo undertakes no obligation to publicly update any forward-looking statements after the date of this document. 23